Inferra AI / Company / ETON
Eton Pharmaceuticals, Inc.
ETON · Health Care
Last earnings Aug 13, 2026
Key results
EPSquarter
$0.14
diluted EPS of $0.14, and Adjusted EBITDA of $5.7 million Received FDA approval for and launched DESMODA Acquired and relaunched HEMANGEOL Announced initiation of ET-700 clinical study
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
Revenuequarter
$24.3 million
First quarter Financial Results Net Revenue: Total net revenue for the first quarter of 2026 was $24.3 million compared to $17.3 million in the prior year period, an increase of 40%.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
Total net revenue in the first quarter of 2025 included $3.3 million of licensing revenue.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
Product sales and royalty revenue were $24.3 million during the first quarter of 2026 compared with $14.0 million in the prior year period, an increase of 73%, driven by strong growth across the portfolio, in particular INCRELEX, ALKINDI SPRINKLE, GALZIN, and Carglumic Acid, and the addition of revenue from KHINDIVI.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
Gross marginquarter
67%
gross margin of 67%, compared to adjusted gross profit of $12.0 million and adjusted
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
gross margin of 69% in the prior year period.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
Corporate revenuequarter
$0.9 million
Of that increase, $0.9 million was attributable to higher FDA annual product fee expenses as Eton no longer qualifies for the FDA s orphan program fee exemption due to exceeding the corporate revenue threshold.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA): Adjusted EBITDA for the first quarter of 2026 was $5.7 million or 24% of revenue, compared to $3.7 million or 21% of revenue in the prior year period.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
AI analysis
Q1 2026 · reported May 14, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · May 14, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q1 2026 | Prior qtr | Year ago |
|---|---|---|---|
| EPS | $0.14 | — | — |
| Revenue | $24.3 million | — | $17.3 million |
| Gross margin | 67% | — | — |
| Corporate revenue | $0.9 million | — | — |
Guidance · company-stated
Direction: Raised
“Guidance The Company now expects 2026 revenues to exceed $120 million, an increase from prior guidance of $110 million.”
Classified from the release's primary full-year outlook statement.
Margin
Capital allocation
Deferred Financing Costs, Debt Discount and Detachable Debt-Related Warrants Costs incurred to issue debt are deferred and recorded as a reduction to the debt balance in the accompanying Condensed Balance Sheets.
The Company amortizes these costs over the expected term of the related debt under the effective interest method.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +393.8% computed from stated figures
Company-stated claims
Historical · increase of 113% · revenue
“Gross Profit: Gross profit for the second quarter of 2026 was $25.4 million compared with $11.9 million in the prior year period, an increase of 113%, primarily due to increased product sales.”
EX-99 · Aug 13, 2026Event summary
Eton Pharmaceuticals, Inc. Q1 2026 — diluted EPS of $0.14, and Adjusted EBITDA of $5.7 million Received FDA approval for and launched DESMODA Acquired and relaunched HEMANGEOL Announced initiation of ET-700 clinical study
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “Guidance The Company now expects 2026 revenues to exceed $120 million, an increase from prior guidance of $110 million.”
Revenue — Raised (“raising”)
“Based on this strong year-to-date performance, we are raising our full year 2026 revenue guidance.”
Revenue — Raised (“increase”)
“Guidance The Company now expects 2026 revenues to exceed $120 million, an increase from prior guidance of $110 million.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Deferred Financing Costs, Debt Discount and Detachable Debt-Related Warrants Costs incurred to issue debt are deferred and recorded as a reduction to the debt balance in the accompanying Condensed Balance Sheets.
SEC original ↗Eton Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 13, 2026
The Company amortizes these costs over the expected term of the related debt under the effective interest method.
SEC original ↗Eton Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 13, 2026
Debt discounts related to the relative fair value of warrants issued in conjunction with debt are also recorded as a reduction to the debt balance and accreted over the expected term into interest expense using the effective interest method.
SEC original ↗Eton Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 13, 2026
Dividends on common stock are assumed to be zero for the BSM valuation of the stock options.
SEC original ↗Eton Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 13, 2026
The Company s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and debt obligation.
SEC original ↗Eton Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 13, 2026
Based on borrowing rates currently available to the Company, the carrying value of the debt obligation approximates its fair value.
SEC original ↗Eton Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 13, 2026
Strategy & priorities
, May 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ( Eton or the Company ) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2026.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
We initiated a clinical study for the KHINDIVI TM label expansion, saw the start of the ET-700 pilot study, and received FDA clearance to proceed with our INCRELEX label harmonization study, which we intend to initiate later this year.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
KHINDIVI label expansion study underway.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2026 were $1.9 million compared to $1.2 million in the prior year period, primarily due to clinical study expenses associated with the KHINDIVI label expansion and increased expenses associated with ET-700 project development activities.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
Risks & headwinds
Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.
SEC original ↗Eton Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026
Patent Costs All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the successful award of a patent and the recovery of the expenditure.
SEC original ↗Eton Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 13, 2026
Earnings deck slides
0 decks with slide viewEton Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
38 documents- Q3 2026
- 8-KETON
Oct 14, 2026
- Q2 2026
- 8-KETON
Sep 28, 2026
- 8-KETON
Aug 13, 2026
- EX-99ETON
- 10-QETON
- 8-KETON
- 8-KETON
- 8-KETON
Jul 29, 2026
- Q1 2026
- 8-KETON
- 8-KETON
May 19, 2026
- EX-99ETON
- 8-KETON
May 14, 2026
- 10-QETON
- 8-KETON
- EX-99ETON
- 8-KETON
Apr 27, 2026
- EX-99ETON
- 8-KETON
Apr 16, 2026
- EX-99ETON
- 8-KETON
Apr 15, 2026
- Q4 2025
- 10-KETON
Mar 19, 2026
- 8-KETON
Mar 19, 2026
- 8-KETON
- EX-99ETON
- 8-KETON
Feb 25, 2026
- EX-99ETON
- 8-KETON
- EX-99ETON
- Q3 2025
- 8-KETON
- 8-K/AETON
- 8-KETON
- 10-QETON
- Q2 2025
- 8-KETON
- 10-QETON
- 8-KETON
- Q1 2025
- 8-KETON
Jun 27, 2025
- 8-KETON
Jun 20, 2025
- 8-KETON
Jun 10, 2025
Earnings releases
8 documentsPresentations
1 document- Q3 2025
- ETONDeck
Transcripts
0 documentsNo transcripts for Eton Pharmaceuticals, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.